Subscribe to Pro or Enterprise plans to unlock this feature.
Become a smarter investor today.
Become a smarter investor today.
This statistic highlights Illumina’s Revenue by Segment, split between Core Illumina and Helix, on a yearly basis from 2014 onwards.
|Revenue by Segment||2014||2015||2016||2017||2018||2019||2020|
(All figures in billions, except percentages)
Illumina initially had two reportable segments: Core Illumina and Helix. Core Illumina dominated the total revenue share every year. The total revenue grew by 74% from $1.861 billion in 2014 to $3.239 billion in 2020. The revenue share of Helix was always very less. On April 25, 2019, Helix was deconsolidated. Illumina now has only one reportable segment, Core Illumina, which includes Illumina’s core operations.
The highest percentage increase in the total revenue was witnessed in the year 2018. The total revenue grew by 21.2% from $2.760 billion in 2017 to $3.344 billion in 2018. The total revenue was in an upward trend from 2014 to 2019. It increased by 90% from $1.861 billion in 2014 to $3.544 billion in 2019, which was the highest revenue the company ever recorded. This exponential increase was followed by a drop of 8.6% in the next year. The total revenue was recorded to be $3.239 billion in 2020.
The products and services of Core Illumina are used by customers in the research, clinical, and applied markets. They enable the adoption of a variety of genomic solutions. Core Illumina constitutes all the company’s operations, except the results of the previously consolidated VIE, Helix.
The revenue generated by Core Illumina increased by 74% from $1.861 billion in 2014 to $3.239 billion in 2020. When Helix existed, even then the entire revenue was generated by Core Illumina. The revenue generated by Core Illumina witnessed the highest percentage increase in the year 2018. The revenue grew by 21.1% from $2.754 billion in 2017 to $3.334 billion in 2018. In the following year, the revenue just increased by 6.3%. It was recorded to be $3.543 billion in 2019. The revenue of Core Illumina has been on an upward trend from 2014 till 2019. However, in 2020, this segment generated a revenue of $3.239 billion which was 8.5% lesser than revenue of $3.543 billion in 2020.
Helix was founded for people to learn more about their genetic information by partnering with third-party companies to provide affordable sequencing and database services to consumers, resulting in the development of a consumer ecosystem.
Helix did not generate any revenue from 2014 to 2016. It generated a revenue of $6 million for the first time in 2017. The revenue grew by 66% in the following year. It was recorded to be $10 million in 2018. However, this segment was de-consolidated in the next year.
Illumina serves customers in the research, clinical, and applied markets with sequencing and array-based solutions. Their products and services make genomic solutions more widely available in research and clinical settings. They were founded in April 1998 in California and renamed in Delaware in July 2000. Their products are mainly used in the fields of life sciences, oncology, reproductive health, agriculture. Pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies are among their customers, as are leading genomic research centers, academic institutions, government laboratories, and hospitals. The genetic analysis becomes faster and easier for the customers because of their integrated sequencing and microarray systems, consumables, and analysis tools. Customers can choose from a variety of genomic complexity, price points, and throughput options in this portfolio, allowing them to find the best solution for their research or clinical application.
Did you like Illumina’s Revenue by Segment statistic?
Access thousands of more such key performance indicator data points, on thousands of US stocks, with Business Quant.
You can get started here.
Always know what you’ll pay. No hidden costs or surprises.
* Billed annually, local taxes extra.
* Local taxes extra.